Anti-tau immunotherapy represents one of the most actively pursued disease-modifying strategies for Alzheimer's disease and related tauopathies. These approaches aim to target pathological tau protein through monoclonal antibodies or active vaccination, with the goal of clearing existing tau pathology and preventing the spread of tau pathology throughout the brain.
Despite significant investment and numerous clinical trials, anti-tau immunotherapy programs have largely failed to demonstrate clinical efficacy. However, the trials have generated important insights into tau biology, biomarkers, and the challenges of treating neurodegenerative diseases. This page provides an overview of the various anti-tau antibody and vaccine programs that have been or are currently being developed.
¶ Tau Biology and Therapeutic Target
Tau is a microtubule-associated protein encoded by the MAPT gene. In its normal state, tau plays essential roles in neuronal biology:
- Microtubule stabilization: Tau binds to microtubules and promotes their polymerization
- Axonal transport: Facilitates transport of vesicles and organelles along axons
- Synaptic function: Modulates synaptic plasticity and neuronal signaling
- Neuronal health: Supports neuronal viability through various mechanisms
In Alzheimer's disease and tauopathies, tau undergoes pathological transformation:
Hyperphosphorylation:
- Abnormal phosphorylation at multiple sites (>80 potential sites)
- Reduces tau's ability to bind microtubules
- Promotes tau misfolding and aggregation
Aggregation:
- Formation of paired helical filaments (PHFs)
- Assembly into neurofibrillary tangles (NFTs)
- Progressive accumulation correlates with cognitive decline
Spread:
- Tau propagates between neurons in a prion-like manner
- Pathological tau appears in connected brain regions over time
- Forms the basis for staging of tau pathology (Braak staging)
Anti-tau immunotherapy is based on several hypotheses:
- Clear existing pathology: Antibodies could bind and facilitate clearance of pathological tau
- Prevent propagation: Neutralize extracellular tau to block spread between neurons
- Reduce toxicity: Remove soluble toxic tau species
- Disease modification: Slow or halt progression by addressing downstream pathology
The largest class of anti-tau antibodies target the N-terminal region of tau, based on the hypothesis that N-terminal antibodies can intercept extracellular tau and prevent propagation.
Developer: Biogen
Mechanism:
- Humanized IgG1 targeting amino acids 6-23 of tau
- Binds to extracellular tau released from neurons
- Intended to prevent tau propagation
Clinical Development:
- Phase I: Completed, showed safety and target engagement
- Phase II TANGO trial: Did not meet primary endpoints in AD
- Phase II in PSP: Did not meet primary endpoints
- Status: Discontinued
Key Learnings:
- Target engagement demonstrated (CSF tau reductions)
- No clinical benefit despite biomarker effects
- Highlighted disconnect between biomarker engagement and clinical outcomes
Developer: AbbVie
Mechanism:
- Humanized antibody targeting N-terminal tau
- Similar mechanism to gosuranemab
Clinical Development:
- Phase I: Completed successfully
- Phase II in PSP: Did not meet primary endpoints
- Phase II in AD: Did not meet primary endpoints
- Status: Discontinued
Key Learnings:
- Autopsy study confirmed brain penetration and target engagement
- Mechanism of action validated but insufficient clinical efficacy
- Suggested that earlier intervention might be needed
Developer: Roche
Mechanism:
- Humanized antibody targeting the mid-region of tau
- Different epitope than N-terminal antibodies
Clinical Development:
- Phase II trials in AD
- Results did not meet primary endpoints
- Status: Discontinued
Key Learnings:
- Mid-region targeting did not provide advantage
- Consistent with failures of other anti-tau approaches
| Antibody |
Company |
Epitope |
Status |
| JNJ-63742057 |
Janssen |
N-terminal |
Phase I/II |
| Lu AF87908 |
Lundbeck |
N-terminal |
Phase I |
| ACI-35 |
AC Immune |
Phospho-tau |
Phase I/II |
Different Epitopes:
- Mid-region targeting
- C-terminal targeting
- Phospho-tau specific antibodies (e.g., targeting pSer396/404)
Enhanced Delivery:
- Antibody engineering for improved brain penetration
- Bispecific antibodies
- Trojan horse approaches
Combination Approaches:
- Anti-tau + anti-amyloid combination
- Anti-tau + small molecule combinations
Active vaccination approaches aim to stimulate the patient's own immune system to produce anti-tau antibodies:
Developer: AC Immune / Janssen
Mechanism:
- Liposome-based vaccine containing phosphorylated tau peptides
- Elicits antibodies targeting pathological phosphorylated tau
- Designed to specifically target disease-relevant tau forms
Development:
- Phase I/II trials in early AD
- Showed safety and immunogenicity
- Antibodies recognized pathological tau species
- Status: Ongoing development
Advantages:
- Could provide continuous antibody production
- Lower cost than repeated antibody infusions
- Phospho-tau specificity may improve safety
- AADvac1 (Axon Neuroscience): Active vaccine targeting pathological tau
- ABV-5: Various approaches in early development
- DNA-based vaccines: Alternative delivery methods
Challenges:
- Immune response variability
- Need for adjuvant to enhance response
- Risk of autoimmune reactions
- Antibody titer maintenance
Tau PET has become essential for anti-tau clinical trials:
Tracers:
- [^18F]flortaucipir (AV-1451): Most widely used
- [^18F]PI-2620: Alternative tracer
- Others in development
Uses:
- Patient selection (tau-positive subjects)
- Baseline pathology assessment
- Monitoring tau accumulation during treatment
- Correlation with clinical outcomes
Limitations:
- Off-target binding in certain brain regions
- Limited sensitivity to early tau changes
- Cannot distinguish functional effects from mere binding
Measures:
- Total tau (t-tau)
- Phosphorylated tau (p-tau181, p-tau217)
- Tau oligomers
- Neurofilament light (NfL) for neurodegeneration
Findings in Trials:
- Many anti-tau antibodies reduce CSF tau
- Biomarker changes do not consistently predict clinical benefit
- Disconnect between target engagement and clinical outcomes
Emerging blood-based biomarkers:
- p-tau217, p-tau181: Highly specific for AD pathology
- NfL: Neurodegeneration marker
- Tau fragments: Potential specific markers
¶ Challenges and Lessons Learned
Multiple factors likely contribute to the lack of clinical efficacy:
Timing:
- Patients may have too much established tau pathology
- Need to treat earlier in disease course
Target Engagement:
- Antibody brain penetration may be insufficient
- May not reach all relevant tau species
Tau Biology Complexity:
- Multiple tau strains with different properties
- Different forms of pathological tau (soluble, insoluble)
- Tau may not be primary driver of neurodegeneration in established disease
Disease Mechanisms:
- Tau may be downstream of other processes (e.g., amyloid)
- Neuronal loss may be too advanced to reverse
Biomarkers:
- Target engagement can be demonstrated
- Biomarker changes do not reliably predict clinical benefit
- Need better biomarkers for patient selection and response
Trial Design:
- Earlier disease stages may be needed
- Tau-positive patient selection is important
- Longer trials may be needed
Combination Approaches:
- Anti-tau alone may be insufficient
- May need to address amyloid first
- Multiple targets may be necessary
Despite failures, several programs continue:
- ACI-35 vaccine: Phospho-tau specific approach
- JN-63742057: Different epitope targeting
- Combination approaches: Anti-tau + anti-amyloid
Tau Degradation:
- PROTAC approaches (protein degradation)
- Autophagy-inducing approaches
Tau Modification:
- Acetylation modulators
- Phosphorylation inhibitors
Gene Therapy:
- Antisense oligonucleotides targeting MAPT
- RNA interference approaches
- Tau strain identification
- Personalized targeting based on pathology
- Biomarker-driven patient selection
| Approach |
Mechanism |
Advantages |
Challenges |
| N-terminal antibodies |
Block extracellular tau |
Target propagation |
Insufficient efficacy |
| Mid-region antibodies |
Bind intracellular tau |
Different target |
Also failed |
| Phospho-tau antibodies |
Target pathological tau |
Specificity |
Still experimental |
| Active vaccines |
Induce anti-tau antibodies |
Long-lasting effect |
Immune response |
| Small molecules |
Inhibit aggregation |
Oral delivery |
Not yet successful |